The Ministry of Health and Family Welfare has notified the Drugs (Eleventh Amendment) Rules, 2026 through G.S.R. 706(E) dated 30 July 2026, introducing specific provisions for debarment of applicants who submit misleading, fake or fabricated documents or information under the Drugs Rules, 1945. “Debarment” has been defined as “the prohibition, exclusion, or disqualification of any person, firm, or entity” from undertaking specified activities relating to drugs, for a specified period or permanently. The amendment introduces debarment provisions across areas including import and registration, sale, manufacture, clinical trials and new drugs, blood centres and approved testing laboratories. The relevant Licensing Authority may debar an applicant after providing an opportunity to show cause and recording reasons in writing. The amendment also provides an appellate mechanism, allowing an aggrieved applicant to appeal within 30 days of receiving the debarment order. Importantly, the provisions also cover submissions made by “any other person on his behalf”, which may have implications for companies relying on consultants, regulatory agents, CROs and other third parties. This places greater emphasis on internal verification and oversight of regulatory submissions. Overall, the amendment signals a clear move towards greater accountability and data integrity, while preserving due process. The New Drugs and Clinical Trials Rules, 2019 already contains a similar debarment provision. This amendment builds on this framework by introducing debarment provisions across various areas under the Drugs Rules, 1945.  About the Authors:  Alishan Naqvee, Founding Partner of LexCounsel Law Offices, is one of India’s leading healthcare and life sciences lawyers, renowned for advising multinational pharmaceutical, biotechnology, medical device and digital health companies on high-value regulatory, commercial and dispute resolution matters.  Amir Shejeed, Associate at LexCounsel Law Offices, is a healthcare and life sciences lawyer with expertise in pharmaceutical and medical device regulation, digital health, AI-enabled healthcare technologies, clinical research, data protection and healthcare compliance.

Feedback